Autoimmune Hemolytic Anemia (AIHA)

Autoimmune hemolytic anemia (AIHA) is a blood disorder where your immune system mistakenly makes antibodies that stick to your own red blood cells. These antibodies mark red cells for destruction in the spleen or liver (extravascular hemolysis) or activate complement and break red cells apart in the bloodstream (intravascular hemolysis). When red cells are destroyed faster than the bone marrow can replace them, you become anemic. Doctors classify AIHA mainly by the temperature at which the antibodies work best—“warm” (near body temperature) or “cold” (at cooler temperatures)—because this affects both symptoms and treatment. PMC+2NCBI+2

Autoimmune hemolytic anemia (AIHA) is a blood disorder where your immune system makes antibodies that wrongly attach to your red blood cells and destroy them faster than your body can replace them. When red blood cells break early (hemolysis), your blood carries less oxygen. That causes tiredness, shortness of breath, fast heartbeat, and sometimes yellow skin (jaundice) or dark urine. Doctors group AIHA by “temperature” of antibody activity: warm AIHA (most common, IgG antibodies active near body temperature) and cold agglutinin disease (CAD) or other cold types (IgM antibodies that stick to red cells in the cold). Treatment depends on the type, how severe the anemia is, and other health issues. Early, targeted care improves symptoms and lowers risks. PMC+1

---

Other names

People and articles may also call this condition: autoimmune haemolytic anaemia (British spelling), warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease (CAD), mixed-type AIHA, paroxysmal cold hemoglobinuria (PCH), immune hemolytic anemia, drug-induced immune hemolytic anemia (DIIHA). These names describe the same overall problem—immune destruction of red blood cells—but point to the antibody type, temperature behavior, or trigger. PMC+4Wiley Online Library+4BSH+4

---

Types

Warm AIHA (wAIHA). The most common type. IgG antibodies bind red cells best at body temperature (about 37 °C). Hemolysis is usually extravascular, mainly in the spleen. Steroids are first-line; rituximab is often used if steroids fail or relapse occurs. PMC+1

Cold agglutinin disease (CAD). Usually due to IgM antibodies that bind red cells in cooler areas (fingers, toes). Complement activation causes hemolysis and cold-induced circulation symptoms (like acrocyanosis). Treatment often targets the B-cell clone or complement (e.g., rituximab-based regimens; complement inhibitors in selected cases). Keeping warm helps symptoms. ASH Publications+1

Mixed-type AIHA. Features of both warm and cold antibodies. Management often combines approaches used for warm and cold disease. NCBI

Paroxysmal cold hemoglobinuria (PCH). A rare form where a special IgG antibody (Donath–Landsteiner antibody) binds to red cells in the cold and triggers complement hemolysis on rewarming, often causing dark urine (hemoglobinuria). Diagnosis uses the Donath–Landsteiner test. PubMed+1

Primary (idiopathic) vs. secondary AIHA. In primary, no underlying cause is found. In secondary, AIHA is linked to another condition (e.g., lymphomas, autoimmune diseases, infections, or certain medicines). About half of AIHA cases are secondary in many series. nssg.oxford-haematology.org.uk+1

---

Causes

1. Idiopathic (primary). No clear trigger is found; the immune system targets red cells on its own. Wiley Online Library

2. Lymphoid cancers (e.g., CLL, lymphoma). Abnormal B cells can make the harmful antibodies. Wiley Online Library

3. Autoimmune diseases (e.g., lupus). Immune misdirection can extend to red cells. ScienceDirect

4. Mycoplasma pneumoniae infection. Can trigger cold agglutinins and hemolysis. PMC

5. Epstein–Barr virus (mono). Sometimes triggers transient AIHA. PMC

6. Cytomegalovirus or other viral infections. Immune cross-reactions can target red cells. PMC

7. COVID-19 (reported cases). Rare immune hemolysis has been described in association. PMC

8. Waldenström macroglobulinemia / cold IgM clones. Clonal IgM causes CAD. ASH Publications

9. Drug-induced (hapten type; e.g., penicillins/cephalosporins). Drug-coated RBCs are targeted. BSH

10. Drug-induced (autoantibody type; e.g., methyldopa historically). Drug triggers anti-RBC autoantibodies. BSH

11. Drug-dependent antibodies (e.g., certain antibiotics). Antibody reacts only when drug is present. BSH

12. Post-transplant immune dysregulation. New immune system may attack recipient RBCs. PMC

13. Common variable immunodeficiency / immune dysregulation syndromes. Autoimmunity can include RBCs. PMC

14. Complement pathway activation disorders. Promote intravascular hemolysis in cold types. ASH Publications

15. Pregnancy/post-partum immune shifts (rare). Autoimmunity may emerge or flare. PMC

16. HIV infection. Immune activation may cause AIHA. PMC

17. Hepatitis C or other chronic infections. Occasional immune hemolysis reported. PMC

18. Solid tumors (less common). Paraneoplastic autoimmunity can involve RBCs. PMC

19. Autoimmune thyroid disease or other organ-specific autoimmunity. Immune disorders cluster. PMC

20. Childhood post-viral PCH. Donath–Landsteiner antibody after infection causes acute hemolysis. PubMed

Note: Specific drugs and proportions vary by region and era; clinicians use a structured work-up to search for these associations. BSH

Symptoms

1. Tiredness and weakness from anemia lowering oxygen delivery.

2. Shortness of breath with activity because tissues get less oxygen.

3. Pale skin or inner eyelids (pallor) from low hemoglobin.

4. Fast heartbeat or palpitations as the body compensates for anemia.

5. Dizziness or light-headedness, especially when standing up.

6. Headache due to less oxygen to the brain.

7. Jaundice (yellow eyes/skin) from bilirubin released as red cells break down.

8. Dark urine (tea- or cola-colored) when hemoglobin spills into urine during intravascular hemolysis.

9. Back or belly pain from rapid hemolysis or a swollen spleen.

10. Enlarged spleen (splenomegaly) because it removes antibody-coated red cells.

11. Cold-induced color changes in fingers/toes (acrocyanosis) in CAD.

12. Sensitivity to cold or symptoms that worsen in the cold (cold types).

13. Chest pain if anemia is severe or if you have heart disease.

14. Fever sometimes with infection-related or acute hemolysis episodes.

15. Poor exercise tolerance from persistent anemia and fatigue. PMC+1

---

Diagnostic tests

A) Physical examination

1) General appearance and vital signs. Doctors look for pallor, jaundice, fever, rapid heartbeat, or low blood pressure that suggest significant hemolysis or anemia severity. ASH Publications

2) Eye and skin exam for jaundice. Yellowing hints at increased bilirubin from red cell breakdown. ASH Publications

3) Spleen and liver palpation. An enlarged spleen is common in warm AIHA; the liver may also enlarge if hemolysis is brisk. PMC

4) Hands/feet inspection in a cool room. Color changes, pain, or numbness suggest cold-related RBC clumping (CAD). ASH Publications

5) Cardiorespiratory exam. Fast heart rate, flow murmurs, or signs of heart strain help gauge the impact of anemia. ASH Publications

B) “Manual” / bedside immunohematology tests

6) Direct antiglobulin test (DAT, direct Coombs). This is the cornerstone test; it detects antibodies and/or complement stuck to your red cells. A monospecific DAT further tells whether IgG, C3d, or both are present—key for classifying warm vs cold types. NCBI+1

7) Elution and antibody identification. If DAT shows IgG, the lab can strip antibodies off red cells (elution) and identify their specificity; this helps with diagnosis and safe transfusion. Meridian

8) Cold agglutinin titer and thermal amplitude. Measures how strong and at what temperatures cold antibodies react; higher thermal amplitude correlates with symptoms and need for therapy. ASH Publications

9) Donath–Landsteiner (DL) test. Confirms PCH by demonstrating a biphasic hemolysin that binds in the cold and lyses on rewarming. PMC+1

10) Crossmatch/compatibility testing strategies. Specialized protocols allow transfusion when autoantibodies interfere; labs aim to provide the “least incompatible” RBCs when urgently needed. ASH Publications

C) Laboratory & pathology tests

11) Complete blood count (CBC) with indices. Shows low hemoglobin, often normal cell size, and sometimes spuriously high mean corpuscular volume in CAD from RBC clumping. NCBI

12) Reticulocyte count. Usually elevated as the marrow tries to replace destroyed RBCs; may be inappropriately low if marrow is suppressed or iron/folate deficient. ASH Publications

13) Hemolysis panel: bilirubin, LDH, haptoglobin. Indirect bilirubin and LDH go up; haptoglobin goes down—classic for hemolysis. ASH Publications

14) Peripheral blood smear. Warm AIHA often shows spherocytes; cold disease can show agglutination; smear also checks for other causes of anemia. ASH Publications

15) Complement markers. Labs may report C3d on DAT (typical in CAD/PCH) or measure complement activity when considering complement-targeted therapy. NCBI

16) Infection work-up (e.g., Mycoplasma, EBV, HIV, hepatitis). Looks for secondary triggers, especially in cold or mixed types. PMC

17) Autoimmune screen (e.g., ANA). Screens for conditions like lupus when secondary AIHA is suspected. ScienceDirect

18) Bone marrow examination (selected cases). If counts don’t recover or another blood disorder is suspected, marrow exam helps rule in/out malignancy or marrow failure. ASH Publications

D) Electrodiagnostic / physiologic monitoring

19) Electrocardiogram (ECG). Not a test “for AIHA” itself, but anemia can stress the heart; ECG helps if you have chest pain, fainting, or heart disease. ASH Publications

20) Pulse oximetry and, when indicated, cardiac/respiratory monitoring. Supports safety in severe anemia or rapid hemolysis episodes. ASH Publications

E) Imaging to look for causes/complications

Abdominal ultrasound for spleen size; CT/PET-CT to look for lymph nodes or a lymphoid cancer; echocardiogram if there are signs of heart strain from severe anemia. These aren’t mandatory for everyone but are helpful when the history and basic labs point toward a secondary cause or a complication. ASH Publications

Non-pharmacological treatments (therapies & other measures)

Each item explains what it is, purpose, and mechanism (how it helps). Where a measure is especially relevant to CAD (cold-type AIHA), I mark it.

1. Thermal protection (keep warm) — Dress in layers, warm gloves/socks/hat, avoid cold rooms, and don’t drink ice-cold fluids.
   Purpose: Prevent cold-triggered red cell clumping and hemolysis in CAD; reduce symptom flares.
   Mechanism: Cold exposure favors IgM binding and complement activation on red cells; warmth reduces antibody binding and complement fixation. Use in all care settings; warm IV fluids. PMC+1

2. Warm transfusion/infusion protocol (hospital) — If you need IV fluids or a blood transfusion, the line and fluids are kept at ~37 °C; cross-matching may be done at 37 °C.
   Purpose: Safe transfusion with fewer reactions in CAD and mixed AIHA.
   Mechanism: Heat prevents cold antibody binding; reduces red cell agglutination during infusion. ASH Publications+1

3. Prompt infection treatment — Seek care early for fevers, cough, urinary symptoms.
   Purpose: Infections can trigger hemolysis flares; treating them prevents worsening anemia.
   Mechanism: Inflammatory cytokines and complement activity increase during infection and can intensify red cell destruction. Frontiers

4. Folic acid supplementation (dietary support; see drugs/supplements below for dose) — Standard supportive care in chronic hemolysis.
   Purpose: Prevent folate deficiency from rapid red cell turnover.
   Mechanism: Folate is required for new red blood cell production; hemolysis increases demand. ASH Publications+1

5. Restrictive transfusion strategy with close monitoring — Transfuse when clearly needed (for example severe symptoms or very low hemoglobin), with hematology guidance.
   Purpose: Balance benefit and risk; transfusions remain safe and effective when indicated.
   Mechanism: Careful thresholds and compatibility processes reduce reactions; RBCs provide immediate oxygen-carrying capacity. PMC+1

6. Thrombosis prevention in high-risk periods — Encourage movement, hydration, and clinician-guided blood clot prevention during severe hemolysis or hospitalization.
   Purpose: Lower risk of clots, which can rise during active hemolysis.
   Mechanism: Hemolysis and inflammation can increase clotting tendency; preventive steps reduce this risk. The Blood Project

7. Medication review and avoidance of triggers — Review all prescriptions, over-the-counter drugs, and herbal products.
   Purpose: Some drugs can induce hemolysis or worsen AIHA; removing them reduces flares.
   Mechanism: Drug-dependent antibodies or oxidative stress can promote red cell destruction. nssg.oxford-haematology.org.uk

8. Vaccination planning (with clinician) — Keep routine vaccines current; time live vaccines carefully around immunosuppressive therapy.
   Purpose: Prevent infections that can trigger hemolysis and avoid vaccine-related complications during immunosuppression.
   Mechanism: Reduced infections = fewer inflammatory triggers of hemolysis; coordinated timing maintains protection. ASH Publications

9. Energy management & graded activity — Pace activities on an anemic day; use short, frequent rests.
   Purpose: Reduce fatigue and dizziness from low oxygen levels.
   Mechanism: Balances oxygen demand with supply while hemoglobin recovers. PMC

10. Nutrition emphasizing folate and general adequacy — Leafy greens, legumes, fortified grains; ensure enough protein and B-vitamins; avoid iron unless a clinician confirms iron deficiency.
    Purpose: Support red cell production; prevent deficiencies.
    Mechanism: Adequate substrates for erythropoiesis; avoids iron overload risk after hemolysis. PMC

11. Thermal/environmental planning for CAD — Choose warm seating in offices/clinics/restaurants, use hand warmers in air-conditioned places, pre-warm bath water.
    Purpose: Everyday strategies to limit inadvertent cold exposure.
    Mechanism: Reduces cold-triggered antibody binding. PMC

12. Psychological support & stress reduction — Counseling, support groups, brief CBT or mindfulness.
    Purpose: Lower anxiety and improve coping with chronic illness and clinic visits.
    Mechanism: Stress hormones can worsen fatigue and sleep; coping skills improve adherence to therapy and self-care. PMC

13. Fall-prevention and safety — Stand slowly, use handrails, hydrate.
    Purpose: Reduce dizziness-related injuries when anemic.
    Mechanism: Orthostatic precautions prevent sudden drops in blood pressure and falls. PMC

14. Sun/heat-safe warming — Use safe warming (layers, warm beverages) rather than hot tubs or saunas if lightheaded.
    Purpose: Warmth without dehydration risk.
    Mechanism: Gentle thermal support avoids vasodilation-induced dizziness. PMC

15. Care plans for procedures — Tell dentists/surgeons you have AIHA; ask for warming blankets and warmed IV fluids as needed (esp. CAD).
    Purpose: Prevent intra-procedural hemolysis.
    Mechanism: Temperature control and careful transfusion practices reduce risk. ASH Publications

16. Occupational & school accommodations — Flexible breaks, room heaters, exemption from cold-room tasks.
    Purpose: Reduce triggers; maintain productivity and attendance.
    Mechanism: Environmental control lowers hemolysis risk in CAD. PMC

17. Travel planning — Avoid very cold destinations or plan protective clothing; carry medical summary.
    Purpose: Keep trips safe and comfortable.
    Mechanism: Prevents cold-triggered hemolysis and ensures access to appropriate transfusion protocols if needed. PMC

18. Home thermometers & humidifiers — Keep indoor temps stable; humid air feels warmer.
    Purpose: Enhance thermal comfort and reduce cold triggers.
    Mechanism: Stable warmth moderates antibody activity in CAD. PMC

19. Sleep optimization — Regular schedule; treat sleep apnea if present.
    Purpose: Combat fatigue and support recovery from anemia.
    Mechanism: Better oxygenation and rest improve energy and cognition. PMC

20. Education on red-flag symptoms — Know signs needing urgent care (chest pain, fainting, very dark urine, severe breathlessness).
    Purpose: Early response lowers risk of complications.
    Mechanism: Rapid evaluation can prevent severe hypoxia or hemolytic crises. PMC

---

Drug treatments

For each: long description (~150 words) with class, typical dose/time (examples; your doctor personalizes this), purpose, mechanism, common side effects. Drug choices depend on warm vs cold AIHA and your situation.

1. Prednisone / Prednisolone (Corticosteroid; first-line for warm AIHA).
   Description & Purpose: Prednisone is usually the first medicine for warm AIHA because it quickly reduces red cell destruction. Many patients improve within days to weeks. It is not very effective for CAD.
   Dose/Time (example): Often ~1 mg/kg/day, then slow taper over months if response; exact plan varies.
   Mechanism: Dampens antibody production and activity of macrophages that remove antibody-coated red cells (extravascular hemolysis).
   Side effects: Mood changes, sleep trouble, high blood sugar, infection risk, bone loss; long tapers help prevent relapse and reduce steroid complications; bone protection (vitamin D, calcium ± bisphosphonate) is often added. Haematologica+1

2. Rituximab (anti-CD20 monoclonal antibody).
   Description & Purpose: Common second-line in warm AIHA and often first-line in CAD when anemia is clinically meaningful. Effective alone or with steroids; responses can be durable.
   Dose/Time (example): 375 mg/m² weekly ×4, or 1000 mg on days 1 and 15 (regimens vary).
   Mechanism: Depletes B-cells that make the harmful antibodies.
   Side effects: Infusion reactions (fever, chills), infections (HBV reactivation risk—screen first), low immunoglobulins with repeated courses; vaccinations should be timed. ASH Publications+1

3. Sutimlimab-jome (ENJAYMO; complement C1s inhibitor) — for CAD.
   Description & Purpose: FDA-approved to reduce transfusion need by stopping classical complement pathway activation in cold agglutinin disease. Improves hemoglobin and lowers hemolysis.
   Dose/Time (example): IV infusions—2 weekly starting doses, then every 2 weeks (weight-based).
   Mechanism: Blocks C1s so complement cannot mark red cells for destruction. Does not fix cold-induced circulatory symptoms (Raynaud’s), so warming is still important.
   Side effects: Infusion reactions, risk of certain infections; vaccines against encapsulated bacteria are recommended per label. FDA Access Data+1

4. Mycophenolate mofetil (MMF; immunosuppressant).
   Description & Purpose: Used for steroid-refractory warm AIHA or to reduce steroid dose.
   Dose/Time (example): Often 500–1000 mg twice daily; onset over weeks.
   Mechanism: Inhibits lymphocyte purine synthesis, lowering autoantibody production.
   Side effects: GI upset, infections, low white cells; requires lab monitoring and contraception counseling. Haematologica

5. Azathioprine (immunosuppressant).
   Description & Purpose: Classic steroid-sparing agent in warm AIHA.
   Dose/Time (example): ~1–2 mg/kg/day; check TPMT activity if available to predict toxicity.
   Mechanism: Purine analog that reduces lymphocyte proliferation and antibody formation.
   Side effects: Low blood counts, liver enzyme rise, infection risk; drug interactions need review. Haematologica

6. Cyclophosphamide (alkylator).
   Description & Purpose: Rescue option for severe, refractory warm AIHA.
   Dose/Time (example): Oral low-dose or intermittent IV; individualized.
   Mechanism: Broad immunosuppression including B-cell effects.
   Side effects: Low counts, infections, hemorrhagic cystitis (use hydration/mesna as indicated), fertility impact—specialist oversight required. Haematologica

7. Cyclosporine A / Tacrolimus (calcineurin inhibitors).
   Description & Purpose: Considered in multi-refractory warm AIHA to curb immune activation.
   Dose/Time (example): Trough-guided dosing with frequent labs.
   Mechanism: Blocks T-cell activation (IL-2 pathway), which indirectly reduces autoantibody help.
   Side effects: Kidney effects, blood pressure rise, tremor, drug interactions. Haematologica

8. Danazol (attenuated androgen).
   Description & Purpose: Older steroid-sparing agent sometimes used in chronic warm AIHA when other options fail.
   Dose/Time (example): e.g., 200–400 mg/day, adjusted.
   Mechanism: Immune modulation via hormone pathways; can improve erythropoiesis.
   Side effects: Weight gain, liver enzyme rise, acne, voice changes; contraception counseling needed. Haematologica

9. Intravenous immunoglobulin (IVIG).
   Description & Purpose: Short-term adjunct in warm AIHA, especially in children, severe crises, or pre-op; often combined with steroids. Responses can be temporary.
   Dose/Time (example): Total 2 g/kg (e.g., 0.4 g/kg/day ×5 or 1 g/kg/day ×2).
   Mechanism: Saturates Fc receptors and FcRn, reducing removal of antibody-coated red cells and accelerating clearance of pathogenic IgG.
   Side effects: Headache, aseptic meningitis, thrombosis risk in predisposed patients; rarely, IVIG can itself cause hemolysis—monitor CBC. PMC+2PMC+2

10. Erythropoiesis-stimulating agents (ESAs; off-label in selected cases).
    Description & Purpose: May help raise hemoglobin when marrow drive is inadequate or during recovery.
    Dose/Time: Individualized dosing with iron/folate evaluation.
    Mechanism: Stimulates red blood cell production; does not treat the autoimmunity itself.
    Side effects: Hypertension, thrombosis; reserved for specific scenarios by specialists. ACP Journals

11. Bortezomib (proteasome inhibitor; specialty use).
    Description & Purpose: Considered in rare, refractory antibody-mediated AIHA to target plasma cells.
    Mechanism: Depletes antibody-producing plasma cells.
    Side effects: Neuropathy, cytopenias; specialist protocols only. ASH Publications

12. Sirolimus (mTOR inhibitor; emerging).
    Description & Purpose: Reported benefit in multi-refractory autoimmune cytopenias, including wAIHA.
    Mechanism: T-cell signaling inhibition, regulatory T-cell effects.
    Side effects: Mouth ulcers, high lipids, infections—monitoring required. ASH Publications

13. Ianalumab (anti-BAFF-R; in trials).
    Description & Purpose: Investigational therapy targeting B-cell survival signaling in wAIHA not controlled by standard lines.
    Mechanism: Blocks BAFF receptor, aiming to reduce autoantibody-producing cells.
    Note: In clinical trials; not routine care yet. PMC

14. Pegcetacoplan (C3 inhibitor; under study for CAD/wAIHA).
    Description & Purpose: Subcutaneous complement inhibitor that has improved hemoglobin and symptoms in studies of CAD and wAIHA; regulatory status varies—consult specialist.
    Mechanism: Inhibits C3-mediated hemolysis.
    Side effects: Injection-site reactions, infection risk; vaccination guidance needed. ASH Publications

15. Fostamatinib (Syk inhibitor; emerging reports).
    Description & Purpose: Targeting Fc-mediated phagocytosis; early data/series in autoimmune cytopenias suggest potential benefit in wAIHA—investigational/off-label.
    Mechanism: Blocks macrophage signaling that drives extravascular hemolysis.
    Side effects: Hypertension, diarrhea; specialist oversight. ASH Publications

16. Plasma exchange (therapeutic apheresis; procedure, not a drug; short-term).
    Description & Purpose: Temporarily removes pathogenic cold IgM antibodies in CAD during severe crises or before surgery.
    Mechanism: Physical removal of circulating antibodies; effect is short-lived; combine with definitive therapy.
    Side effects: Line complications, shifts in electrolytes; done in hospital. Medscape

17. IV methylprednisolone (pulse) in crisis.
    Description & Purpose: When hemolysis is very severe in wAIHA, short pulses can quickly suppress immune activity before transitioning to oral taper.
    Mechanism: Rapid anti-inflammatory/immunosuppressive effect.
    Side effects: Similar to steroids; used acutely under monitoring. ASH Publications

18. Combination rituximab + bendamustine (selected CAD).
    Description & Purpose: Used by specialists for more durable B-cell control in CAD when monotherapy is insufficient.
    Mechanism: B-cell depletion (rituximab) plus cytotoxic effect (bendamustine).
    Side effects: Neutropenia, infections; vaccination and prophylaxis may be needed. ASH Publications

19. Tranexamic acid is generally not used to treat hemolysis (clarification).
    Purpose/Mechanism: Hemolysis is immune/complement-mediated, not a bleeding from fibrinolysis problem; antifibrinolytics do not help red cell destruction.
    Note: Included to prevent misinformation; discuss with your clinician. PMC

20. Support bundles with steroids (bone protection & GI protection).
    Description & Purpose: When on long steroids, add vitamin D, calcium, ± bisphosphonate; consider PPI if GI risk.
    Mechanism: Offsets steroid bone loss and ulcer risk; standard supportive care.
    Side effects: Based on each agent; your clinician tailors choices. PMC

---

Dietary molecular supplements

Supplements never replace medical therapy. Evidence is strongest for folic acid in hemolysis; other items have supporting but variable evidence mainly for general immune or nutritional support.

1. Folic acid — Dose: commonly 1 mg daily (doctor may adjust).
   Function/Mechanism: Replaces folate consumed by rapid red cell production in hemolysis; helps bone marrow make healthy new cells and prevents megaloblastic changes. Standard supportive care in AIHA. ASH Publications+1

2. Vitamin B12 (if deficient) — Dose: as tested (oral or injections).
   Function/Mechanism: Corrects B12 deficiency that can worsen anemia or cause neuropathy; only take if labs show need. PMC

3. Vitamin D (bone & immune support) — Dose: per blood level.
   Function/Mechanism: Supports bone health during steroid therapy; may modulate immune responses; evidence in AIHA is supportive/indirect. PMC

4. Protein-rich nutrition (whey or equivalents, if diet is inadequate) — Dose: dietitian-guided.
   Function/Mechanism: Supplies amino acids for hemoglobin and red cell membrane repair; helps recovery from anemia. PMC

5. Omega-3 fatty acids — Dose: food-first (fish), supplements only if advised.
   Function/Mechanism: General anti-inflammatory effects; indirect support for symptoms; not a disease-modifying AIHA therapy. PMC

6. Multivitamin without iron (unless iron-deficient) — Dose: daily standard.
   Function/Mechanism: Covers minor gaps; avoids unnecessary iron which can accumulate after hemolysis unless a true deficiency exists. PMC

7. Thiamine (B1) and riboflavin (B2) via diet — Dose: diet-first.
   Function/Mechanism: Support cellular energy and red cell enzymes; routine nutrition focus. PMC

8. Probiotics/fermented foods — Dose: food-first.
   Function/Mechanism: Gut support; evidence in AIHA is limited; avoid during profound immunosuppression unless your doctor approves. PMC

9. Antioxidant-rich foods (berries, greens) — Dose: diet-first.
   Function/Mechanism: General oxidative stress balance; supportive, not curative. PMC

10. Hydration strategy — Dose: steady fluids unless restricted.
    Function/Mechanism: Supports circulation and kidney handling of hemolysis by-products; simple but helpful. PMC

---

Immunity-booster / Regenerative / Stem-cell oriented” drugs

There are no proven stem-cell pills for AIHA. The items below are immune-modulating or complement-targeting medicines that reduce hemolysis by changing immune activity (100-word summaries).

1. Rituximab — Dose: see above.
   Function/Mechanism: Reduces B-cells that create pathogenic antibodies; helps both wAIHA and CAD. Not a classic “booster,” but an immune re-balancer. ASH Publications

2. Sutimlimab (C1s inhibitor) for CAD — Dose: every-2-weeks infusions after loading.
   Function/Mechanism: Blocks complement at the start (C1s), preventing downstream red cell destruction; improves anemia and transfusion need in CAD. FDA Access Data

3. Pegcetacoplan (C3 inhibitor; in studies) — Dose: per study protocols.
   Function/Mechanism: Inhibits complement centrally at C3, reducing hemolysis; promising trial data in CAD/wAIHA. ASH Publications

4. IVIG — Dose: short courses.
   Function/Mechanism: Temporarily saturates Fc receptors and neonatal Fc receptor to reduce removal of antibody-coated red cells and increase clearance of harmful IgG. PMC

5. Sirolimus (mTOR inhibitor; emerging) — Dose: monitored by levels.
   Function/Mechanism: Immune-reprogramming effects (T-cell pathways) reported helpful in refractory autoimmune cytopenias. ASH Publications

6. Bortezomib (plasma-cell targeting; selected refractory cases) — Dose: specialist regimens.
   Function/Mechanism: Depletes antibody-producing plasma cells when other therapies fail. ASH Publications

---

Surgeries / Procedures

1. Splenectomy (spleen removal; mainly warm AIHA).
   Procedure: Laparoscopic or open surgery to remove the spleen.
   Why done: In selected adults with relapsed/refractory warm AIHA when medical therapy fails or causes unacceptable side effects. Can reduce red cell destruction and steroid need. Requires pre-/post-op vaccines and infection precautions lifelong. PMC+1

2. Central venous access device placement (port/PICC).
   Procedure: Minor procedure for long-term IV treatments (rituximab, complement inhibitors).
   Why done: Reliable access reduces needle sticks and protects veins during repeated infusions. FDA Access Data

3. Therapeutic plasma exchange (apheresis; short-term) — see also under drugs.
   Procedure: Machine removes plasma (with antibodies) and returns cells with replacement fluid.
   Why done: Temporary control in CAD before surgery or during severe hemolytic crises while definitive therapy starts. Medscape

4. Bone marrow biopsy (diagnostic, not curative).
   Procedure: Needle sample of bone marrow.
   Why done: Clarify cause when diagnosis is unclear, rule out other marrow diseases that can mimic or accompany AIHA. Guides therapy choices. PMC

5. Vaccination series (peri-splenectomy or complement blockade) — protocolized.
   Procedure: Immunization against encapsulated organisms (e.g., pneumococcus, meningococcus, Hib) timed before/after surgery or complement inhibitors.
   Why done: Reduce serious infection risk when spleen is removed or complement is blocked. FDA Access Data

---

Preventions

1. Avoid cold exposure (CAD). Dress warmly; protect head/face/hands/feet; avoid cold drinks and cold IV fluids. Prevents antibody binding and hemolysis. PMC

2. Treat infections early. Call your clinician for fever or new infection signs. Reduces hemolysis triggers. Frontiers

3. Keep vaccines up to date (timed with therapy). Prevents infections that can trigger flares. ASH Publications

4. Take folic acid if your clinician recommends it. Prevents deficiency during hemolysis. ASH Publications

5. Review all medicines and supplements with your care team. Avoid possible hemolysis triggers. nssg.oxford-haematology.org.uk

6. Plan safe transfusions when needed (warming for CAD; restrictive thresholds). Safer support when anemia is severe. Medscape+1

7. Move, hydrate, and use thrombosis prevention in high-risk periods. Lowers clot risk during active hemolysis. The Blood Project

8. Bone protection during steroids (vitamin D, calcium, ± bisphosphonate). Prevents fractures. PMC

9. Structured follow-up with hematology. Catches relapses early and optimizes tapering. ASH Publications

10. Carry a medical summary noting AIHA type and transfusion warming needs. Speeds safe care during emergencies. ASH Publications

---

When to see a doctor

Call your clinician promptly if you notice worsening fatigue, shortness of breath, chest pain, fainting, very dark/brown urine, new yellowing of skin/eyes, or fever. These may signal active hemolysis or complications that need treatment changes, transfusion, or infection work-up. If you have CAD, seek help for cold-triggered color changes in fingers/toes or pain that does not improve with warming. During treatment, report signs of infection (especially on rituximab or after splenectomy) and any sudden blood pressure, glucose, mood, or bone pain changes on steroids. PMC+1

---

What to eat and what to avoid

Eat: a folate-rich pattern (dark leafy greens, beans/lentils, citrus, fortified grains), adequate protein (eggs, fish, poultry, legumes), and a variety of fruits/vegetables for overall nutrients and antioxidants. Maintain steady hydration unless restricted. This supports your marrow as it makes new red cells. PMC

Avoid or limit: iron supplements unless your doctor confirms deficiency; many people with hemolysis do not need extra iron. Avoid ice-cold drinks if you have CAD. Limit alcohol (can worsen anemia and immunity). Be cautious with new herbal products or over-the-counter pills that might interact with immunosuppressants or trigger hemolysis—always check with your team. PMC+1

---

Frequently asked questions

1. Is AIHA curable?
   Some people achieve long-lasting remission, especially with rituximab or after splenectomy in selected warm AIHA cases. Others need long-term management to control flares. Haematologica

2. What is the main difference between warm AIHA and CAD?
   Warm AIHA uses IgG at body temperature and often responds to steroids; CAD involves IgM that binds in the cold and is best managed with warming, rituximab, or complement inhibitors (e.g., sutimlimab). ASH Publications+1

3. Do steroids always work?
   They help most people with warm AIHA, but not CAD; careful tapering and second-line agents are often needed for durable control. Haematologica

4. Are blood transfusions safe in AIHA?
   Yes—when clearly indicated and done with hematology oversight. In CAD, warm the patient/line; overall effectiveness is high and serious reactions are uncommon. Medscape+1

5. Why is folic acid recommended?
   Hemolysis burns through folate; daily folic acid helps the marrow replace red cells. ASH Publications

6. What about iron pills?
   Only if blood tests show iron deficiency; otherwise they are unnecessary and sometimes harmful. PMC

7. Do I need special vaccines?
   Yes, if you’re getting rituximab or having a splenectomy or starting complement inhibitors—your team will time pneumococcal/meningococcal/Hib and other vaccines. FDA Access Data

8. Can lifestyle alone control CAD?
   Thermal protection helps, but many patients with significant anemia need medical therapy such as rituximab or sutimlimab. PMC

9. Is plasmapheresis a long-term fix?
   No, it’s a temporary bridge for CAD during crises or before procedures while definitive therapy takes effect. Medscape

10. Which medicine works fastest?
    Steroids often act quickly in wAIHA; sutimlimab rapidly reduces hemolysis in CAD. Your clinician will choose based on type and severity. Haematologica+1

11. What are the biggest risks of treatment?
    Infections (from immunosuppression), steroid complications (bone loss, glucose), and rare infusion reactions—teams mitigate these with vaccines, monitoring, and supportive care. ASH Publications

12. Could my AIHA be secondary to another disease?
    Yes—AIHA can be primary or secondary (for example, to lymphoid cancers, autoimmune disease, infections, or drugs). Doctors evaluate for these at diagnosis. PMC

13. How long will I need treatment?
    Varies—some need months; others, especially CAD, may need ongoing therapy to keep hemolysis controlled. ASH Publications

14. Are new therapies coming?
    Yes—complement inhibitors (like pegcetacoplan) and BAFF-R antibodies (like ianalumab) are in trials and expanding options. ASH Publications+1

15. What should my emergency card say?
    Your AIHA type; need for warming of infusions/transfusions (if CAD); current medicines (e.g., rituximab, steroids, sutimlimab); and hematology contact. ASH Publications

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 29, 2025.